Background Adherence to treatment is an indicator of treatment success. Long-term data on adherence to biologic treatment in psoriasis are lacking.
Objectives To compare the TNF-α inhibitors regarding drug survival rate and safety in patients with psoriasis.
Methods This study is based on data from the Danish nationwide database DERMBIO covering patients with psoriasis treated with a biologic agent. All patients, who received anti-TNFα treatment in academic referral centers, were included. Baseline data, adverse events, time on treatment and reason for stopping treatment were recorded. Hazard ratios (HRs) for factors determining drug ...
Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris is a post from: Skincare
Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris via BuzzBlazer.com
No comments:
Post a Comment